A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.
What Are The Drugs Involved
The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.
The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.
These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.
What Could This Mean For Bowel Cancer Treatment In The Future
The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.
All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.
Credit: AI
Unlike many other cancers, cervical cancer is considered highly preventable through a combination of HPV vaccination, regular screening, and timely treatment of precancerous lesions.
India has recorded a significant decline in cervical cancer burden, with new cases falling by 37% over the past decade, according to data from the Indian Council of Medical Research's (ICMR) National Cancer Registry Programme (NCRP).
Experts say widespread screening, awareness, and increasing uptake of the human papillomavirus (HPV) vaccine have contributed to the milestone.
The latest estimates show that the number of new cervical cancer cases has dropped from approximately 1.27 lakh annually to around 79,000, marking a major public health milestone in the fight against one of the most common cancers affecting Indian women.
"Cervical cancer is one of the few cancers that can largely be prevented through timely screening and vaccination," Dr. Amitabh Shankar, Head of Preventive Oncology at Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, AIIMS, was quoted as saying.
He attributed the decline to improved awareness, wider availability of screening services, and the gradual expansion of HPV vaccination.
According to experts, early detection through routine cervical cancer screening allows precancerous changes to be identified and treated before they develop into cancer.
At the same time, HPV vaccination protects against high-risk strains of the human papillomavirus, the leading cause of cervical cancer.
The report suggests that increased access to healthcare services, government-led awareness initiatives, and preventive programs have played an important role in reducing the cases of cervical cancer.
Despite the progress, specialists caution that cervical cancer continues to be a major health concern in India, particularly in rural and underserved regions where screening coverage and HPV vaccination remain limited.
They emphasize that expanding HPV vaccination among eligible adolescents, strengthening population-based screening programs, and improving early diagnosis will be essential to prevent it.
The human papillomavirus causes more than 200 known infections. While some types lead to benign skin warts, others are responsible for severe health threats, such as cervical, throat, anal, and penile cancers.
The HPV vaccine provides strong protection against the most lethal strains, avoiding long-term health complications. It helps the immune system recognize and fight off high-risk strains of the virus before they cause harm. It protects against:
Cervix is located in the pelvic cavity, about 3 to 6 inches inside the vaginal canal. It serves as the entrance to the uterus to the vagina. As per the World Health Organization (WHO), almost all cervial cancer are linked to human papillomaviruses (HPV) which are transmitted through sexual contact
Cervical cancer has no symptoms in the early days and therefore, is hard to detect until it has spread. Early-stage cervical cancer symptoms include:
Credit: iStock
Takeda Biopharmaceuticals India today announced that QDENGA (TAK-003) has become the first dengue vaccine to receive approval in India, marking a major milestone in the country's fight against the mosquito-borne disease.
The Drug Controller General of India (DCGI) has granted market authorization for QDENGA to prevent dengue in individuals aged 4-60 years. According to Takeda, it is India's first approved dengue vaccine and can be administered regardless of previous dengue infection, without requiring pre-vaccination testing.
"Since its launch in 2022, QDENGA has been approved in 43 countries, with more than 32 million doses distributed globally. This approval marks an important step forward in strengthening dengue prevention in India," said Dr. Mahender Nayak, Head of Intercontinental Markets.
The approval comes at a critical time as dengue cases in India have risen sharply over the past two decades.
India accounts for nearly one-third of the global dengue burden. In 2025, more than 113,000 dengue cases were officially reported, although modelling studies suggest the true number of infections may run into tens of millions annually due to underreporting.
Rapid urbanization, climate change and widespread mosquito breeding have made dengue a year-round public health concern. Since there is no specific antiviral treatment for dengue, prevention remains the most effective strategy.
"India carries a substantial dengue burden, and all four dengue virus serotypes co-circulate in several regions. QDENGA is designed to protect against all four serotypes regardless of prior exposure," said Dr. Goh Choo Beng, Medical Affairs Head, Southeast Asia & India Cluster.
The DCGI approval is supported by Takeda's global clinical development programme comprising 19 Phase 1, 2 and 3 clinical trials involving more than 28,000 participants in dengue-endemic and non-endemic regions.
The pivotal Phase III TIDES (DEN-301) study enrolled more than 20,000 participants across eight countries and evaluated the vaccine's long-term safety and effectiveness.
Key findings include:
The approval is also supported by an Indian Phase III (DEN-302) trial involving participants aged 4-60 years, which found QDENGA to be safe, well-tolerated and immunogenic in children, adolescents and adults.
Read More: Dengue Is Spreading Beyond Monsoons And Into New Regions Across India, Says Expert
QDENGA (TAK-003) is a live-attenuated tetravalent dengue vaccine designed to protect against all four dengue virus serotypes.
It is administered as two 0.5 mL subcutaneous doses, given three months apart.
The vaccine is built on a DENV-2 backbone, incorporating structural proteins from DENV-1, DENV-3 and DENV-4 to provide broad immune protection.
The World Health Organization (WHO) recommends QDENGA for use in dengue-endemic settings without the need for pre-vaccination screening. The vaccine is also included in the WHO List of Prequalified Vaccines, allowing procurement through agencies such as UNICEF and PAHO.
The vaccine has been approved in 43 countries across Asia, Latin America and Europe. It is already part of Brazil's National Immunization Program and is available through public immunization programmes in Argentina, Colombia and Indonesia.
The vaccine is approved in India for people aged 4-60 years to help prevent dengue disease.
Takeda had partnered with Indian vaccine manufacturer Biological E in 2024 to expand production of QDENGA.
Under the agreement, Biological E plans to manufacture 50 million doses annually, supporting Takeda's goal of producing 100 million doses globally each year by the end of the decade.
Credit: AI
A minimally invasive treatment that targets only cancerous tissue in the prostate may offer the same chance of treating localized prostate cancer as surgery or radiotherapy while causing significantly fewer side effects, according to a major UK study.
The findings suggest that focal therapy, which destroys only the tumor while preserving the healthy parts of the prostate, could become a viable treatment option for carefully selected patients.
It could help reduce common risks like urinary incontinence and erectile dysfunction that follow conventional treatment.
The study, presented by University College London (UCL) and collaborating institutions, compared long-term outcomes of men treated with focal therapy against those receiving radical prostatectomy or radiotherapy.
Researchers found that cancer control was comparable across the treatment groups, while men undergoing focal therapy experienced substantially better functional outcomes.
"This study shows that men with localized prostate cancer do not necessarily have to choose between effective cancer treatment and preserving their quality of life," said Professor Caroline Moore, Professor of Urology at University College London.
"Our results demonstrate that focal therapy can control cancer effectively in appropriately selected men while significantly reducing the side effects associated with whole-gland treatments."
Unlike surgery, which removes the entire prostate, or radiotherapy, which treats the whole gland, focal therapy targets only the cancer with the help of high-intensity focused ultrasound (HIFU). By sparing healthy tissue and surrounding nerves, the treatment aims to preserve urinary and sexual function.
According to the researchers, the study provides strong evidence that focal therapy can offer outcomes similar to standard treatments in men whose cancer is confined to a specific area of the prostate.
Professor Moore cautioned that focal therapy for prostate cancer may not be suitable for every patient. "It is important that men undergo careful assessment with high-quality imaging and biopsy so that we can identify those who are most likely to benefit from this treatment," she said.
The researchers also emphasized that patients receiving focal therapy require ongoing follow-up, including prostate-specific antigen (PSA) testing and imaging, to monitor any recurrence or progression of disease.
Also read: Broadcaster Lauren Laverne Shares 'Smoldering Myeloma' Diagnosis After Cancer Recovery
The findings have drawn renewed public attention after television presenter Jeremy Clarkson recently disclosed that he underwent treatment for prostate cancer.
Clarkson revealed that he chose a treatment that reduced long-term side effects, raising awareness about prostate cancer, and the importance of early diagnosis.
Prostate cancer is among the most commonly diagnosed cancers in men worldwide. While surgery and radiotherapy remain the standard treatments for localized disease, both can result in complications like urinary leakage, bowel problems and erectile dysfunction that can affect the quality of life.
Experts say the new findings support a growing shift toward more personalized treatment strategies that balance cancer treatment with quality of life.
© 2024 Bennett, Coleman & Company Limited